Loading candles…
Jubilant Pharmova Ltd is a global integrated pharmaceuticals company that operates across the pharmaceutical value chain, including drug discovery, development, and the commercialization of generics and proprietary novel drugs. The company engages in several business segments such as pharmaceuticals, contract research and development services, radiopharmaceuticals, allergy immunotherapy, contract manufacturing, and proprietary novel drugs. It maintains a leading position in the North American radiopharmaceutical market and focuses on a diversified business model targeting high-growth, innovation-driven sectors. Jubilant Pharmova's activities span industries including pharmaceuticals, radiopharmaceuticals, and allergy immunotherapy, with a significant presence in North America.
This page is a live market overview for JUBILANT PHARMOVA LTD (JUBLPHARMA) on the NSE. As a listed security, JUBILANT PHARMOVA LTD is tracked in the Healthcare segment of the Indian cash market and is widely followed for price discovery, liquidity and sector exposure. Use this overview to review price action, session ranges and derivatives context for JUBLPHARMA before placing trades on tick2trade.
As of the latest feed, JUBLPHARMA last traded at ₹932 on NSE, up ₹5.75 (0.62%) from the previous close of ₹926.25. Today's session range is ₹914.4 – ₹945, against a 52-week band of ₹786.05 – ₹1,184.8. Traded volume today stands at 1.68L shares.
The overview consolidates an interactive price chart with multiple time ranges, recent market headlines, upcoming corporate events for JUBLPHARMA in one place so you do not need multiple screens during the session. Day and 52-week ranges help you judge whether JUBLPHARMA is trading near support, resistance or the middle of its recent band. Volume and depth, when available, add context on how aggressively the name is being bought or sold.
Equity overview pages are built for investors who want a single reference for JUBILANT PHARMOVA LTD before reading news, checking results or sizing a position. Corporate events and headlines in the side column surface catalysts that may explain sudden moves in JUBLPHARMA. Related stocks in the same sector appear at the bottom of the page for quick peer comparison.
For a full option chain with greeks, open-interest bias, max pain and multi-leg strategy tools, open the tick2trade terminal or visit the dedicated JUBLPHARMA option chain page linked from this overview.
| Results - FY26 | To consider and approve the financial results for the period ended Jun 30, 2026 | 7 Aug 2026 |
| Results - FY26 | To consider and approve the financial results for the period ended March 31, 2026 and dividend | 22 May 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended December 31, 2025 | 6 Feb 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended Jun 30, 2025 | 29 Jul 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended March 31, 2025 and dividend | 16 May 2025 |
Tick2trade is a brand/platform owned and operated by Besseggen InfoTech LLP, a SEBI Registered Stock Broker holding Registration No: INZ000213450, Member of NSE (Member Code: 90155) and BSE (Member Code: 6722). Investment in securities market are subject to market risks; read all related documents carefully before investing.